PTAB Upholds DNA Testing Patents Key To $272M Ravgen Win
By Jasmin Boyce ( April 19, 2023, 6:45 PM EDT) -- The Patent Trial and Appeal Board has rejected biotechnology company Streck's contention that nearly 30 claims in a Ravgen genetic testing patent are obvious or anticipated, siding with the patent owner in yet another challenge to the testing system it had used to score $272 million in infringement damages in underlying litigation....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.